Two decade trends in cardiovascular disease outcomes and cardiovascular risk factors among US veterans living with HIV

Haji, Mohammed; Lopes, Vrishali; Ge, Augustus; Halladay, Christopher; Soares, Cullen; Shah, Nishant; Longenecker, Christopher T.; Lally, Michelle; Bloomfield, Gerald S.; Shireman, Theresa I.; Ross, David A.; Sullivan, Jenny L.; Rudolph, James L.; Wu, Wen‐Chih; Erqou, Sebhat

doi:10.1016/j.ijcrp.2022.200151

Cited by 2 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persons with HIV (PWH) have an increased risk of atherosclerotic cardiovascular disease (ASCVD) [1][2][3]. In addition, as life expectancy with HIV has improved, PWH are experiencing an even greater incidence of age-related diseases such as cardiovascular disease (CVD) [4,5]. Despite this increased risk, prior studies have found that most PWH have not discussed CVD risk with their HIV providers [6].…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease

McLaughlin

Durstenfeld

Gandhi

et al. 2023

Aids

View full text Add to dashboard Cite

Objectives: We sought to characterize atherosclerotic cardiovascular disease (ASCVD) risk and metrics of CV health in persons with HIV (PWH) eligible for primary prevention of ASCVD. Design: Cross-sectional study of PWH 40 years and older without documented ASCVD who received care at three HIV clinics in San Francisco from 2019-2022. Methods: We used ICD-10 codes and electronic health record data to assess ASCVD risk and CV health, as defined by the American Heart Association's Life's Essential 8 (LE8) metrics for nicotine exposure, body mass index (BMI), lipids, glucose, and blood pressure (BP). Results: Among 2567 PWH eligible for primary prevention of ASCVD, the median age was 55 years, 14% were female, and 95% were on antiretroviral therapy. Seventy-seven percent had undergone complete assessment of ASCVD risk factors, and 50% of these patients had intermediate-high ASCVD risk (≥7.5%). Of those with hypertension, 39% were prescribed an anti-hypertensive. Among those eligible, 43% were prescribed a statin. The mean LE8 CV health score (0 to 100 [best health]) was 55.1 for nicotine exposure, 71.3 for BMI, 70.4 for lipids, 81.2 for blood glucose, 56.0 for BP, with an average score of 66.2 across the five metrics. Patients with Medicare insurance, Black patients, and those with sleep apnea and chronic kidney disease had on average lower CV health scores; patients with undetectable viral loads had higher CV health scores. Conclusions: We highlight opportunities for improving primary prevention of ASCVD among PWH, especially in the areas of guideline-based therapy, nicotine exposure, and BP control.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease

McLaughlin

Durstenfeld

Gandhi

et al. 2023

Aids

View full text Add to dashboard Cite

show abstract

“…The survival of people living with human immunodeficiency virus (HIV) (PLHIV) has improved since the introduction of antiretroviral therapy (ART) [ 1 , 2 , 3 , 4 ]. HIV infection has become a chronic disease associated with a persistent inflammatory status that increases the probability of complications not related to acquired immunodeficiency syndrome (AIDS), such as non-AIDS defining neoplasms or cardiovascular disease [ 5 , 6 , 7 ]. Anal squamous cell carcinoma (ASCC) is one of the most frequent non-AIDS-defining neoplasms, with an incidence ranging from 85 × 100,000 p-y in MSM to 22 × 100,000 p-y in women [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

HPV Infection of the Oropharyngeal, Genital and Anal Mucosa and Associated Dysplasia in People Living with HIV

Hidalgo-Tenorio,

Calle-Gómez,

Moya-Megías

et al. 2023

Viruses

View full text Add to dashboard Cite

Background: The main objectives were to describe the prevalence of HPV, its genotypes and HPV-associated dysplastic lesions in the oropharyngeal mucosa of PLHIV and related factors. Material and Methods: This cross-sectional prospective study consecutively enrolled PLHIV attending our specialist outpatient units. At visit, HIV-related clinical and analytical variables were gathered, and oropharyngeal mucosa exudates were taken to detect HPV and other STIs by polymerase chain reaction. Samples were also taken from the anal canal of all participants and from the genital mucosa of the women for HPV detection/genotyping and cytological study. Results: The 300 participants had a mean age of 45.1 years; 78.7% were MSM and 21.3% women; 25.3% had a history of AIDS; 99.7% were taking ART; and 27.3% had received an HPV vaccine. HPV infection prevalence in the oropharynx was 13%, with genotype 16 being the most frequent (2.3%), and none had dysplasia. Simultaneous infection with Treponema pallidum (HR: 4.02 (95% CI: 1.06–15.24)) and a history of anal HSIL or SCCA (HR: 21.52 (95% CI: 1.59–291.6)) were risk factors for oropharyngeal HPV infection, whereas ART duration (8.8 vs. 7.4 years) was a protective factor (HR: 0.989 (95% CI: 0.98–0.99)). Conclusions: The prevalence of HPV infection and dysplasia was low in the oropharyngeal mucosae. A higher exposure to ART was protective against oral HPV infection.

show abstract

Two decade trends in cardiovascular disease outcomes and cardiovascular risk factors among US veterans living with HIV

Cited by 2 publications

References 51 publications

Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease

Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease

HPV Infection of the Oropharyngeal, Genital and Anal Mucosa and Associated Dysplasia in People Living with HIV

Contact Info

Product

Resources

About